XML 61 R72.htm IDEA: XBRL DOCUMENT v2.4.0.6
Acquisitions - Additional Information (Detail) (USD $)
In Thousands, unless otherwise specified
12 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended 12 Months Ended
Nov. 19, 2009
Diagnostics [Member]
Sep. 30, 2012
Sirigen Group Limited [Member]
Aug. 24, 2012
Sirigen Group Limited [Member]
Sep. 30, 2012
Sirigen Group Limited [Member]
Minimum [Member]
Sep. 30, 2012
Sirigen Group Limited [Member]
Maximum [Member]
Sep. 30, 2012
Sirigen Group Limited [Member]
Patent [Member]
Sep. 30, 2012
Sirigen Group Limited [Member]
Patent assets acquired [Member]
Sep. 30, 2012
Sirigen Group Limited [Member]
Developed technology [Member]
Sep. 30, 2012
KIESTRA Lab Automation BV [Member]
Feb. 09, 2012
KIESTRA Lab Automation BV [Member]
Sep. 30, 2012
Carmel Pharma [Member]
Sep. 30, 2011
Carmel Pharma [Member]
Sep. 30, 2012
Carmel Pharma [Member]
Medical [Member]
Sep. 30, 2012
Accuri Cytometers, Inc [Member]
Mar. 17, 2011
Accuri Cytometers, Inc [Member]
Mar. 17, 2011
Accuri Cytometers, Inc [Member]
Biosciences [Member]
Mar. 17, 2011
Personal flow cytometry technology [Member]
Sep. 30, 2012
HandyLab, Inc [Member]
Jun. 30, 2010
HandyLab, Inc [Member]
Nov. 19, 2009
HandyLab, Inc [Member]
Jun. 30, 2010
Platform Technology [Member]
Nov. 19, 2009
Platform Technology [Member]
Sep. 30, 2012
Jaguar Plus Platform technology [Member]
Nov. 19, 2009
Jaguar Plus Platform technology [Member]
Business Acquisition [Line Items]                                                
Percentage of outstanding shares acquired     100.00%             100.00%   100.00%     100.00%         100.00%        
Acquisition-date fair value of consideration transferred net of in cash acquired   $ 64,433 $ 64,433           $ 59,457 $ 59,457 $ 287,111 $ 287,111   $ 204,970 $ 204,970     $ 277,610            
Fair value of consideration transferred in cash     52,533             50,891               274,756            
Cash acquired in acquisition     878             5,176   5,047     3,112                  
Fair value of the contingent consideration     11,900             8,566                            
Patent   10,700                                            
Risk-adjusted discount rate           20.00%                                    
Amortization of technology, expected useful life           14 years   16 years 10 years                              
Developed technology   19,100             12,581         111,500                    
Risk-adjusted discount rate             22.00%   14.50%                              
Acquired in-process research and development   11,600             7,416         42,300     42,300 169,000   169,000   26,000   143,000
Technological and commercial risk   80.00%             100.00%                              
Risk-adjusted discount rate used to determine fair value of in-process research and development assets acquired       24.00% 26.00%       15.50%                              
Goodwill 147,456 36,614             33,520   145,386   145,386 93,464   93,464   147,456            
Portion of goodwill expected to be deductible for tax purposes   0             0   0     0       0            
Acquisition related costs in the current period   1,300             2,000   5,250     900       2,500            
Amount reclassified from initial IPR&D valued                                         26,000   143,000  
Useful life assigned to amount reclassified from Net core Dev. Tech                                   14 years 20 years          
Unamortized balance at acquisition date                                       2,854        
Terms related to initial payment for exclusive distribution rights (in years)                                   12 years            
Gain or loss from acquisition                                       $ 0